Stroke Prevention in the Wisconsin Native American Population
4 other identifiers
interventional
120
1 country
2
Brief Summary
This project will develop a "Stroke Awareness Team" including training of Oneida Health Service Coaches working in partnership with the UW team for a population-based health awareness program. This team will develop a series of Oneida Nation Healthy Living and Stroke Awareness Events (from now on health events) to provide education as to the severity of the problem as well as our standard therapies for lifestyle change and risk factor avoidance. This will include education of the healthy members of the tribe including the children to identify signs of stroke and TIA in their elders as well as to develop healthy lifestyles at the earliest of ages to influence the elders to modify their risks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable stroke
Started Apr 2021
Longer than P75 for not_applicable stroke
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 6, 2020
CompletedFirst Posted
Study publicly available on registry
May 11, 2020
CompletedStudy Start
First participant enrolled
April 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedDecember 18, 2025
May 1, 2025
4.5 years
May 6, 2020
December 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (11)
Change in Incidence of Stroke or TIA
Number of incidences of stroke or TIA during the study
baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Diastolic Blood Pressure
Number of Participants with diastolic blood pressure \< 90 mmHg
baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Systolic Blood Pressure
Number of Participants with systolic blood pressure \< 140 mmHg
baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Total Cholesterol
Number of Participants with total cholesterol \< 200 mg/dL
baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Low Density Lipoprotein Cholesterol (LDL-C)
Number of Participants with LDL-C \< 100 mg/dL
baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for High Density Lipoprotein Cholesterol (HDL-C)
Number of Participants with HDL-C \> 60 mg/dL
baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Blood Sugar
Number of Participants with A1c \< 7.5
Baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Body Mass Index (BMI)
Number of Participants who improve BMI
Baseline and 2 years
Change in Number of Participants that meet AHA Simple Rules for Smoking Status
Number of Participants who Smoke
baseline and 2 years
Change in TabCAT Score
The Tablet-based Cognitive Assessment Tool will examine avorites (rote verbal learning and memory), match (processing speed), flanker (executive functions), and line orientation (visuospatial abilities).
baseline and 2 years
Change in Montreal Cognitive Assessment (MoCA) Vancouver Island Coastal First score
Montreal Cognitive Assessment will assess vascular cognitive decline
baseline and 2 years
Secondary Outcomes (5)
Change in Plaque Area
baseline and 2 years
Change in pulsatility index in carotid arteries
baseline and 2 years
Correlation of carotid plaque grayscale texture features (grayscale median values [no units]) to stroke risk factors
baseline and 2 years
Change in Circulating Dipeptidyl Peptidase (DPPIV)
Baseline and 2 years
Change in Circulating Galectin3 (Gal-3)
baseline and 2 years
Other Outcomes (2)
Change in Serum microRNA
baseline and 2 years
Compliance Rates
2 years
Study Arms (3)
High Risk- intense coaching
OTHERage ≥ 55 with MORE than three of the following risk factors: * History of TIA/Stroke * History of Coronary Artery disease * History of Hypertension and/or current elevated blood pressure * History of Diabetes * Current smoker * BMI ≥30
High Risk - standard care
OTHERage ≥ 55 with MORE than three of the following risk factors: * History of TIA/Stroke * History of Coronary Artery disease * History of Hypertension and/or current elevated blood pressure * History of Diabetes * Current smoker * BMI ≥30
Low risk - control
OTHERage ≥ 55 with LESS than three of the following risk factors: * History of TIA/Stroke * History of Coronary Artery disease * History of Hypertension and/or current elevated blood pressure * History of Diabetes * Current smoker * BMI ≥30
Interventions
The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face. Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis.
The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
Eligibility Criteria
You may qualify if:
- Participants receiving health care through the Oneida Health Council Program
- Participants deemed to be at high risk for stroke by modified Framingham assessment of medical history, including cerebral cardiovascular symptomatology, hypertension, diabetes, smoking, BMI
- Willingness to participate in the study, including two-year follow-up
- Controls will be selected using the same criteria with the exception that upon screening, they are not deemed to be at high risk for stroke.
You may not qualify if:
- Presence of established dementia
- Inability to participate in physical and exercise programs due to preexisting disability
- Illiteracy
- Prior carotid procedure altering ultrasound finding
- Presence of medical condition precluding participation or follow-up over a two-year period of time.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Wisconsin, Madisonlead
- Wisconsin Partnership Programcollaborator
Study Sites (2)
University of Wisconsin-Madison
Madison, Wisconsin, 53792, United States
Oneida Comprehensive Health Division
Oneida, Wisconsin, 54155, United States
Related Publications (38)
Harris R, Nelson LA, Muller C, Buchwald D. Stroke in American Indians and Alaska Natives: A Systematic Review. Am J Public Health. 2015 Aug;105(8):e16-26. doi: 10.2105/AJPH.2015.302698. Epub 2015 Jun 11.
PMID: 26066955BACKGROUNDBerman SE, Wang X, Mitchell CC, Kundu B, Jackson DC, Wilbrand SM, Varghese T, Hermann BP, Rowley HA, Johnson SC, Dempsey RJ. The relationship between carotid artery plaque stability and white matter ischemic injury. Neuroimage Clin. 2015 Aug 22;9:216-22. doi: 10.1016/j.nicl.2015.08.011. eCollection 2015.
PMID: 26448914BACKGROUNDDarwish MA, Hammon WM. Studies on Japanese B encephalitis virus vaccines from tissue culture. VI. Development of a hamster kidney tissue culture inactivated vaccine for man. 3. Potency testing of an attenuated strain of OCT-541. J Immunol. 1966 May;96(5):878-84. No abstract available.
PMID: 4288023BACKGROUNDWesley UV, Hatcher JF, Ayvaci ER, Klemp A, Dempsey RJ. Regulation of Dipeptidyl Peptidase IV in the Post-stroke Rat Brain and In Vitro Ischemia: Implications for Chemokine-Mediated Neural Progenitor Cell Migration and Angiogenesis. Mol Neurobiol. 2017 Sep;54(7):4973-4985. doi: 10.1007/s12035-016-0039-4. Epub 2016 Aug 15.
PMID: 27525674BACKGROUNDAmersfoort J, Schaftenaar FH, Douna H, van Santbrink PJ, Kroner MJ, van Puijvelde GHM, Quax PHA, Kuiper J, Bot I. Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner. Atherosclerosis. 2018 Aug;275:214-224. doi: 10.1016/j.atherosclerosis.2018.06.015. Epub 2018 Jun 13.
PMID: 29960897BACKGROUNDHochmeister S, Engel O, Adzemovic MZ, Pekar T, Kendlbacher P, Zeitelhofer M, Haindl M, Meisel A, Fazekas F, Seifert-Held T. Lipocalin-2 as an Infection-Related Biomarker to Predict Clinical Outcome in Ischemic Stroke. PLoS One. 2016 May 6;11(5):e0154797. doi: 10.1371/journal.pone.0154797. eCollection 2016.
PMID: 27152948BACKGROUNDGreenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clin Trials. 2008;5(1):5-13. doi: 10.1177/1740774507087703.
PMID: 18283074BACKGROUNDVermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003 Mar 27;348(13):1215-22. doi: 10.1056/NEJMoa022066.
PMID: 12660385BACKGROUNDTyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol. 2007 Jun 1;165(11):1231-8. doi: 10.1093/aje/kwm085. Epub 2007 Apr 12.
PMID: 17431012BACKGROUNDMitchell CC, Stein JH, Cook TD, Salamat S, Wang X, Varghese T, Jackson DC, Sandoval Garcia C, Wilbrand SM, Dempsey RJ. Histopathologic Validation of Grayscale Carotid Plaque Characteristics Related to Plaque Vulnerability. Ultrasound Med Biol. 2017 Jan;43(1):129-137. doi: 10.1016/j.ultrasmedbio.2016.08.011. Epub 2016 Oct 5.
PMID: 27720278BACKGROUNDJackson DC, Sandoval-Garcia C, Rocque BG, Wilbrand SM, Mitchell CC, Hermann BP, Dempsey RJ. Cognitive Deficits in Symptomatic and Asymptomatic Carotid Endarterectomy Surgical Candidates. Arch Clin Neuropsychol. 2016 Feb;31(1):1-7. doi: 10.1093/arclin/acv082. Epub 2015 Dec 10.
PMID: 26663810BACKGROUNDDempsey RJ, Jackson DC, Wilbrand SM, Mitchell CC, Berman SE, Johnson SC, Meshram NH, Varghese T, Hermann BP. The Preservation of Cognition 1 Year After Carotid Endarterectomy in Patients With Prior Cognitive Decline. Neurosurgery. 2018 Mar 1;82(3):322-328. doi: 10.1093/neuros/nyx173.
PMID: 28575478BACKGROUNDDempsey RJ, Varghese T, Jackson DC, Wang X, Meshram NH, Mitchell CC, Hermann BP, Johnson SC, Berman SE, Wilbrand SM. Carotid atherosclerotic plaque instability and cognition determined by ultrasound-measured plaque strain in asymptomatic patients with significant stenosis. J Neurosurg. 2018 Jan;128(1):111-119. doi: 10.3171/2016.10.JNS161299. Epub 2017 Mar 10.
PMID: 28298048BACKGROUNDMitchell CC, Wilbrand SM, Kundu B, Steffel CN, Varghese T, Meshram NH, Li G, Cook TD, Salamat MS, Dempsey RJ. Transcranial Doppler and Microemboli Detection: Relationships to Symptomatic Status and Histopathology Findings. Ultrasound Med Biol. 2017 Sep;43(9):1861-1867. doi: 10.1016/j.ultrasmedbio.2017.04.025. Epub 2017 Jun 20.
PMID: 28645797BACKGROUNDWang X, Jackson DC, Mitchell CC, Varghese T, Wilbrand SM, Rocque BG, Hermann BP, Dempsey RJ. Classification of Symptomatic and Asymptomatic Patients with and without Cognitive Decline Using Non-invasive Carotid Plaque Strain Indices as Biomarkers. Ultrasound Med Biol. 2016 Apr;42(4):909-18. doi: 10.1016/j.ultrasmedbio.2015.11.025. Epub 2016 Jan 5.
PMID: 26778288BACKGROUNDWang X, Jackson DC, Varghese T, Mitchell CC, Hermann BP, Kliewer MA, Dempsey RJ. Correlation of cognitive function with ultrasound strain indices in carotid plaque. Ultrasound Med Biol. 2014 Jan;40(1):78-89. doi: 10.1016/j.ultrasmedbio.2013.08.001. Epub 2013 Oct 11.
PMID: 24120415BACKGROUNDRocque BG, Jackson D, Varghese T, Hermann B, McCormick M, Kliewer M, Mitchell C, Dempsey RJ. Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements. J Neurol Sci. 2012 Nov 15;322(1-2):20-4. doi: 10.1016/j.jns.2012.05.020. Epub 2012 Jun 1.
PMID: 22658531BACKGROUNDMcCormick M, Varghese T, Wang X, Mitchell C, Kliewer MA, Dempsey RJ. Methods for robust in vivo strain estimation in the carotid artery. Phys Med Biol. 2012 Nov 21;57(22):7329-53. doi: 10.1088/0031-9155/57/22/7329. Epub 2012 Oct 18.
PMID: 23079725BACKGROUNDDempsey RJ, Vemuganti R, Varghese T, Hermann BP. A review of carotid atherosclerosis and vascular cognitive decline: a new understanding of the keys to symptomology. Neurosurgery. 2010 Aug;67(2):484-93; discussion 493-4. doi: 10.1227/01.NEU.0000371730.11404.36.
PMID: 20644437BACKGROUNDShi H, Varghese T, Dempsey RJ, Salamat MS, Zagzebski JA. Relationship between ultrasonic attenuation, size and axial strain parameters for ex vivo atherosclerotic carotid plaque. Ultrasound Med Biol. 2008 Oct;34(10):1666-77. doi: 10.1016/j.ultrasmedbio.2008.02.014. Epub 2008 May 19.
PMID: 18490099BACKGROUNDWang X, Mitchell CC, Varghese T, Jackson DC, Rocque BG, Hermann BP, Dempsey RJ. Improved Correlation of Strain Indices with Cognitive Dysfunction with Inclusion of Adventitial Layer with Carotid Plaque. Ultrason Imaging. 2016 May;38(3):194-208. doi: 10.1177/0161734615589252. Epub 2015 May 28.
PMID: 26025578BACKGROUNDMeshram NH, Varghese T, Mitchell CC, Jackson DC, Wilbrand SM, Hermann BP, Dempsey RJ. Quantification of carotid artery plaque stability with multiple region of interest based ultrasound strain indices and relationship with cognition. Phys Med Biol. 2017 Jul 17;62(15):6341-6360. doi: 10.1088/1361-6560/aa781f.
PMID: 28594333BACKGROUNDBarnett PA, Spence JD, Manuck SB, Jennings JR. Psychological stress and the progression of carotid artery disease. J Hypertens. 1997 Jan;15(1):49-55. doi: 10.1097/00004872-199715010-00004.
PMID: 9050970BACKGROUNDPavlovic-Hournac M, Delbauffe D. Protein metabolism in hypo- and hyperstimulated rat thyroid glands. II. Degradation of newly formed thyroidal proteins. Horm Metab Res. 1976 Jan;8(1):55-61. doi: 10.1055/s-0028-1093673.
PMID: 1248791BACKGROUNDNicolaides AN, Kakkos SK, Kyriacou E, Griffin M, Sabetai M, Thomas DJ, Tegos T, Geroulakos G, Labropoulos N, Dore CJ, Morris TP, Naylor R, Abbott AL; Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. J Vasc Surg. 2010 Dec;52(6):1486-1496.e1-5. doi: 10.1016/j.jvs.2010.07.021.
PMID: 21146746BACKGROUNDSztajzel R, Momjian S, Momjian-Mayor I, Murith N, Djebaili K, Boissard G, Comelli M, Pizolatto G. Stratified gray-scale median analysis and color mapping of the carotid plaque: correlation with endarterectomy specimen histology of 28 patients. Stroke. 2005 Apr;36(4):741-5. doi: 10.1161/01.STR.0000157599.10026.ad. Epub 2005 Feb 10.
PMID: 15705933BACKGROUNDMitchell CC, Korcarz CE, Tattersall MC, Gepner AD, Young RL, Post WS, Kaufman JD, McClelland RL, Stein JH. Carotid artery ultrasound texture, cardiovascular risk factors, and subclinical arterial disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Br J Radiol. 2018 Apr;91(1084):20170637. doi: 10.1259/bjr.20170637. Epub 2018 Jan 31.
PMID: 29308915BACKGROUNDWelsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology. 1994 Apr;44(4):609-14. doi: 10.1212/wnl.44.4.609.
PMID: 8164812BACKGROUNDFillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, Tariot PN, Silverman JM, Clark CM, Welsh-Bohmer KA, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement. 2008 Mar;4(2):96-109. doi: 10.1016/j.jalz.2007.08.005.
PMID: 18631955BACKGROUNDHeyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, Peterson BL, Pieper CF. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to Establish a Registry for Alzheimer's Disease. Neurology. 1998 Jul;51(1):159-62. doi: 10.1212/wnl.51.1.159.
PMID: 9674796BACKGROUNDWelsh KA, Fillenbaum G, Wilkinson W, Heyman A, Mohs RC, Stern Y, Harrell L, Edland SD, Beekly D. Neuropsychological test performance in African-American and white patients with Alzheimer's disease. Neurology. 1995 Dec;45(12):2207-11. doi: 10.1212/wnl.45.12.2207.
PMID: 8848195BACKGROUNDFillenbaum GG, Burchett BM, Unverzagt FW, Rexroth DF, Welsh-Bohmer K. Norms for CERAD constructional praxis recall. Clin Neuropsychol. 2011 Nov;25(8):1345-58. doi: 10.1080/13854046.2011.614962. Epub 2011 Oct 13.
PMID: 21992077BACKGROUNDWhyte SR, Cullum CM, Hynan LS, Lacritz LH, Rosenberg RN, Weiner MF. Performance of elderly Native Americans and Caucasians on the CERAD Neuropsychological Battery. Alzheimer Dis Assoc Disord. 2005 Apr-Jun;19(2):74-8. doi: 10.1097/01.wad.0000165508.67993.a3.
PMID: 15942324BACKGROUNDEllis G, Rodger J, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. Age Ageing. 2005 Jul;34(4):389-92. doi: 10.1093/ageing/afi075. No abstract available.
PMID: 15955759BACKGROUNDVemuganti R. All's well that transcribes well: non-coding RNAs and post-stroke brain damage. Neurochem Int. 2013 Nov;63(5):438-49. doi: 10.1016/j.neuint.2013.07.014. Epub 2013 Aug 15.
PMID: 23954844BACKGROUNDVorlicek J, Mechl Z. [Nephrologic complications of oncologic therapy]. Cas Lek Cesk. 1985 Dec 13;124(50):1561-2. No abstract available. Czech.
PMID: 4084961BACKGROUNDMitchell CC, Wilbrand SM, Hess T, Riesenberg A, Danforth D, Wesley UV, Schwartz ES, Varghese T, Blohowiak CJ, Vandenberg C, Metoxen MF, Lane K, Dempsey RJ. Cerebrovascular Risk Factors for Body Mass Index, Diabetes, and Atherosclerosis in a Wisconsin Native American Population: A Cross-Sectional Observation Study. J Am Heart Assoc. 2026 Mar 4:e043224. doi: 10.1161/JAHA.125.043224. Online ahead of print.
PMID: 41778537DERIVEDCress HJ, Mitchell CC, Wilbrand SM, Wesley UV, Morel Valdes GM, Hess T, Varghese T, Maybock J, Metoxen M, Riesenberg A, Vandenberg C, Blohowiak CJ, Kennard J, Danforth D, Dempsey RJ. Methods in Stroke Prevention in the Wisconsin Native American Population. Neuroepidemiology. 2024;58(4):300-309. doi: 10.1159/000536426. Epub 2024 Jan 31.
PMID: 38295773DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert Dempsey, MD
University of Wisconsin, Madison
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 6, 2020
First Posted
May 11, 2020
Study Start
April 14, 2021
Primary Completion
October 1, 2025
Study Completion
October 1, 2025
Last Updated
December 18, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share
Following transparency and reproducibility guidelines (NIH NOT-OD-15-103), the data resulting from this research proposal will be made publicly available. This will help ensure that other researchers are able to reproduce and/or extend our findings, and will enhance the scientific rigor of this proposal. Data will be made available for download to any individual or organization who requests data and abides by a data-sharing agreement that will be developed. This agreement will require that the data be used solely for research, that individuals or organizations secure the data using conventional electronic safeguards, and that once data analysis is complete, the data be destroyed. In general, data acquired in this study will be made available publicly after initial key manuscripts have been accepted for publication. Manuscripts will include relevant methodological details to allow for reproducibility by other researchers and the ability to extend or findings.